Previewing the 2024 Symposium on Clinical Interventional Oncology Agenda

Edward Kim, MD, Director of Interventional Oncology at Mount Sinai Medical Center, New York, New York, and a guest course director for Symposium on Clinical Interventional Oncology (CIO) discusses what he is most excited for in the upcoming 2024 program.

Check out the full program agenda here.

Transcript:

Hey, I’m Ed Kim, one of the guest course directors for CIO in 2024. Just talking about what I'm excited for at CIO.

I'll say that like CIO every year, I'm excited for the practical applications that CIO offers in interventional oncology with expert faculty from all over the world, really, sharing their practical applications when it comes to interventional oncology.

This year, again, I am excited to look at the Year in Review, in terms of data and the roundtable discussion that happens in a multidisciplinary format for HCC, as well as for metastatic disease. I'm also excited in terms of, I think it's new this year, bringing your data to tumor board. And it's kind of in a debate format. For instance, you could have a solitary HCC and debating ablation versus radiation segmentectomy, also with [musculoskeletal] MSK interventions, you could have locoregional therapy vs radiotherapy. So, a lot of the practical aspects that come at our institutions when it comes to Tumor Board.

Challenging what the best mode of therapy is for patients, I think that will be an exciting part of CIO 2024.